Analysts expect Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) to announce earnings of ($0.56) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Spring Bank Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.52) and the lowest estimate coming in at ($0.63). Spring Bank Pharmaceuticals reported earnings per share of ($0.29) in the same quarter last year, which suggests a negative year over year growth rate of 93.1%. The company is expected to report its next earnings results on Wednesday, August 7th.
On average, analysts expect that Spring Bank Pharmaceuticals will report full-year earnings of ($2.18) per share for the current year, with EPS estimates ranging from ($3.19) to ($1.83). For the next year, analysts forecast that the firm will post earnings of ($2.99) per share, with EPS estimates ranging from ($4.07) to ($2.30). Zacks’ EPS averages are a mean average based on a survey of analysts that follow Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.20.
SBPH has been the topic of several analyst reports. Cantor Fitzgerald set a $9.00 target price on Evofem Biosciences and gave the stock a “buy” rating in a report on Friday, April 12th. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Chardan Capital set a $10.00 target price on Arcimoto and gave the stock a “buy” rating in a report on Friday, April 12th. Piper Jaffray Companies set a $40.00 target price on Schlumberger and gave the stock a “buy” rating in a report on Monday, July 1st. Finally, Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday, May 13th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $19.30.
Shares of Spring Bank Pharmaceuticals stock traded up $0.06 during trading on Friday, reaching $5.12. The stock had a trading volume of 38,317 shares, compared to its average volume of 57,733. The company has a market cap of $84.19 million, a P/E ratio of -2.74 and a beta of 0.37. The business’s fifty day simple moving average is $4.69. Spring Bank Pharmaceuticals has a 52 week low of $3.58 and a 52 week high of $15.00. The company has a quick ratio of 12.11, a current ratio of 12.11 and a debt-to-equity ratio of 0.06.
In other Spring Bank Pharmaceuticals news, Director Scott Andrew Smith purchased 12,000 shares of the stock in a transaction on Friday, June 28th. The shares were purchased at an average price of $4.09 per share, with a total value of $49,080.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martin J. Driscoll purchased 10,000 shares of the stock in a transaction on Tuesday, April 30th. The shares were acquired at an average cost of $7.34 per share, for a total transaction of $73,400.00. The disclosure for this purchase can be found here. Insiders have purchased 42,000 shares of company stock worth $242,930 in the last quarter. 15.60% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its position in Spring Bank Pharmaceuticals by 1,395.4% during the first quarter. BNP Paribas Arbitrage SA now owns 2,946 shares of the company’s stock worth $31,000 after buying an additional 2,749 shares during the last quarter. Rhumbline Advisers increased its position in Spring Bank Pharmaceuticals by 65.3% during the fourth quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock worth $174,000 after buying an additional 6,623 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Spring Bank Pharmaceuticals during the fourth quarter worth approximately $206,000. Bank of New York Mellon Corp increased its position in Spring Bank Pharmaceuticals by 5.9% during the fourth quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock worth $454,000 after buying an additional 2,430 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Spring Bank Pharmaceuticals by 8.7% during the fourth quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock worth $1,214,000 after buying an additional 9,398 shares during the last quarter. 42.93% of the stock is currently owned by hedge funds and other institutional investors.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).
Recommended Story: Rule of 72
Get a free copy of the Zacks research report on Spring Bank Pharmaceuticals (SBPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.